Evaluation of Peroral Endoscopic Myotomy to Treat Zenker's Diverticulum
Launched by METHODIST HEALTH SYSTEM · Dec 9, 2021
Trial Information
Current as of November 05, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is an observational study looking at Zenker’s diverticulum treated with ZPOEM (a procedure to relieve swallowing problems). It combines a retrospective review of past cases at Methodist Health System with a prospective registry of patients who have, or will have, the ZPOEM procedure at that system. The goal is to learn how patients do after ZPOEM, focusing on swallowing symptoms and weight changes, using data from 2017 through 2025. This isn’t testing a new drug or randomized treatment; researchers will analyze existing records and follow patients over time to see patterns in outcomes.
Who can be eligible? Adults 18 and older with Zenker’s diverticulum who have had ZPOEM at Methodist Health System, and those who will have the procedure and agree to be in the registry. For the registry part, you must be able to provide informed consent. What to expect if you participate: researchers will gather information from your medical records, and if you join the prospective registry, they may contact you to answer questions about your symptoms after surgery. Follow-up is planned at about 2 weeks and 3 months after the procedure. Data will be de-identified and shared only with Baylor Scott & White; there is no sharing of individual patient data, and the study is enrolling by invitation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years of age or older
- • Any patient of the physicians listed in this study who has undergone the ZPOEM procedure to treat ZD at MHS
- • For prospective registry: Ability to give informed consent
- Exclusion Criteria:
- • For prospective registry: Unable or not willing to provide informed consent
About Methodist Health System
Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Prashant Kedia, MD
Principal Investigator
Methodist Health System
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials